Vemurafenib

Nature Reviews Drug Discovery

Volumn 10, Issue 11, 2011, Pages 811-812

  Flaherty, Keith T ^a   Yasothan, Uma ^b   Kirkpatrick, Peter ^c  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b IQVIA   (United States)

^c Nature Reviews Drug Discovery ^*  (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; B RAF KINASE INHIBITOR; DABRAFENIB; DACARBAZINE; GSK 2118436; INTERLEUKIN 2; IPILIMUMAB; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE KINASE; RAS PROTEIN; UNCLASSIFIED DRUG; VEMURAFENIB;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER SURVIVAL; DRUG APPROVAL; DRUG COST; DRUG EFFICACY; DRUG INDICATION; DRUG MEGADOSE; DRUG POTENCY; DRUG RESPONSE; DRUG SAFETY; DRUG SPECIFICITY; DRUG STRUCTURE; ENZYME INHIBITION; HUMAN; INOPERABLE CANCER; MELANOMA; METASTASIS; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; DRUG RESISTANCE, NEOPLASM; HUMANS; INDOLES; MELANOMA; PROTO-ONCOGENE PROTEINS B-RAF; SULFONAMIDES;

EID: 80155151884     PISSN: 14741776     EISSN: 14741784     Source Type: Journal    
DOI: 10.1038/nrd3579     Document Type: Article

References (9)

1. Garbe, C. et al. Systematic review of medical treatment in melanoma: current status and future prospects. Oncologist 16, 5-24 (2011).
2. Hodi, F. S. et al. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 363, 711-723 (2010).
3. Davies, H. et al. Mutations of the BRAF gene in human cancer. Nature 417, 949-954 (2002). (Pubitemid 34716871)
4. Tsai, J. et al. Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity. Proc. Natl Acad. Sci. USA 105, 3041-3046 (2008). (Pubitemid 351723664)
5. Bollag, G. et al. Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma. Nature 467, 596-599 (2010).
6. US Food and Drug Administration. FDA labeling information - Zelboraf. FDA website [online], http://www.accessdata.fda.gov/drugsatfda-docs/label/2011/ 202429s000lbl.pdf (2011).
7. Flaherty, K. T. et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N. Engl. J. Med. 363, 809-819 (2010).
8. Chapman, P. B. et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N. Engl. J. Med. 364, 2507-2516 (2011).
9. Boni, A. et al. Selective BRAFV600E inhibition enhances T-cell recognition of melanoma without affecting lymphocyte function. Cancer Res. 70, 5213-5219 (2010).